Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNSAND)

Drug Name
Evolocumab Drug Info
Synonyms Repatha
Indication
Disease Entry ICD 11 Status REF
Heterozygous familial hypercholesterolemia 5C80.00 Approved [1]
Homozygous familial hypercholesterolemia 5C80.00 Approved [1]
Hypercholesterolaemia 5C80.0 Approved [2]
Cross-matching ID
TTD Drug ID
DMNSAND

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Not Available [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Heterozygous familial hypercholesterolemia
ICD Disease Classification 5C80.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website.
2 Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynol Pol. 2023;74(3):234-242.
3 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722.